I'm LongbridgeAI, I can summarize articles.Opaleye Management Inc. increased its stake in Sol-Gel Technologies (SLGL) by purchasing 529 shares valued at $39,041 on July 10, 2026. Concurrently, Mizuho initiated coverage with a positive stance, citing the potential of SGT-610 for Gorlin syndrome. TipRanks' AI Analyst rates SLGL as Neutral due to improving financials offset by losses, while technical sentiment signals a Buy.
New insider activity at Sol-Gel Technologies ( (SLGL) ) has taken place on July 10, 2026.
Opaleye Management Inc., a significant shareholder in Sol-Gel Technologies, has increased its stake by purchasing 529 shares of the company’s stock. This latest transaction, valued at $39,041, underscores Opaleye’s continued confidence in Sol-Gel Technologies and adds to the institutional interest surrounding the stock.
Sol-Gel Technologies saw fresh analyst attention in the last 24 hours as Mizuho initiated coverage, attributing its positive stance mainly to SGT-610’s potential as a first-in-class FDA-approved therapy to prevent new basal cell carcinoma lesions in Gorlin syndrome. The firm emphasized the drug’s validated mechanism, existing off-label systemic hedgehog inhibitor use, and a perceived underappreciation of Sol-Gel’s Gorlin opportunity at current share levels, which together underpinned the revised outlook and supported recent stock strength.
Spark’s Take on SLGL Stock
According to Spark, TipRanks’ AI Analyst, SLGL is a Neutral.
The score is driven primarily by improving financial trajectory (strong 2025 revenue rebound, positive operating/free cash flow, and very low debt) tempered by continued losses and equity erosion. Technicals are mixed/neutral, and valuation is pressured by a negative P/E and no dividend yield.
To see Spark’s full report on SLGL stock,
click here.
More about Sol-Gel Technologies
YTD Price Performance: 81.21%
Average Trading Volume: 33,657
Technical Sentiment Signal: Buy
Current Market Cap: $244.4M